搜尋
Quoin Pharmaceuticals Ltd
QNRX添加自選
4.580USD
-0.130-2.76%
收盤 07/02, 13:00（美東）報價延遲15分鐘
314.38M總市值
虧損本益比TTM
關鍵數據
4.660今開
4.770最高
39.13K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.06%換手率
4.710昨收
4.530最低
142.81K成交額
虧損本益比靜
35.83市淨率
0.00%股息率 TTM
-118.61%ROA
41.80052週最高
0.59量比
-8.96M淨利潤
68.64M總股本
-10.0599每股盈餘TTM
1.58Beta
-231.18%ROE
4.55052週最低
5.09%振幅
--毛利率
314.38M總市值
1.22回報/風險
8.03%風險率
TradingKey Quoin Pharmaceuticals Ltd股票評分
單位: USD 更新時間: 2026-07-02操作建議
Quoin Pharmaceuticals Ltd當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名198/387位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為21.40。中期看，股價處於下降通道。近一個月，市場表現較強，基本面評分較高，但較強的走勢沒有得到技術面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Quoin Pharmaceuticals Ltd評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
Quoin Pharmaceuticals Ltd亮點
亮點風險
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
利潤高增長
公司淨利潤處於行業前列，最新年度總收入0.00美元
估值低估
公司最新PE估值-0.46，處於3年歷史低位
機構加倉
最新機構持股874.98K股，環比增加29.68%
分析師目標
基於
4
分析師
買入
評級
21.400
目標均價
+354.35%
漲幅空間
Quoin Pharmaceuticals Ltd新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Quoin Pharmaceuticals Ltd簡介
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
公司代碼QNRX
公司Quoin Pharmaceuticals Ltd
CEOMyers (Michael)
網址https://quoinpharma.com/
相關品種
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%熱門品種
52828.000
-24.900 (-0.05%)
29655.600
-14.300 (-0.05%)
7505.400
-2.400 (-0.03%)
14954.000
-9.000 (-0.06%)
69577.000
-99.000 (-0.14%)
6406.200
-6.200 (-0.10%)
68.344
-0.339 (-0.49%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4181.460
+6.850 (+0.16%)
常見問題
Quoin Pharmaceuticals Ltd(QNRX)的當前股價是多少？
Quoin Pharmaceuticals Ltd(QNRX)的當前股價是 4.58。
Quoin Pharmaceuticals Ltd 的股票代碼是什麼？
Quoin Pharmaceuticals Ltd的股票代碼是QNRX。
Quoin Pharmaceuticals Ltd股票的52週最高點是多少？
Quoin Pharmaceuticals Ltd股票的52週最高點是41.80。
Quoin Pharmaceuticals Ltd股票的52週最低點是多少？
Quoin Pharmaceuticals Ltd股票的52週最低點是4.55。
Quoin Pharmaceuticals Ltd的市值是多少？
Quoin Pharmaceuticals Ltd的市值是314.38M。
現在Quoin Pharmaceuticals Ltd(QNRX)的股票是買入、持有還是賣出？
根據分析師評級，Quoin Pharmaceuticals Ltd(QNRX)的總體評級為買入，目標價格為21.40。
Quoin Pharmaceuticals Ltd(QNRX)股票的每股收益（EPS TTM）是多少
Quoin Pharmaceuticals Ltd(QNRX)股票的每股收益（EPS TTM）是-517.87。